IRIL Study (AMaRC 18-02)
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma.
The purpose of this study is to determine whether Isatuximab (a new drug), when combined with chemotherapy, improves response to treatment.
Participating sites can enroll patient into study at the outset, which will then ensure patient can access Isatuximab upon failure to achieve CR at cycle 9.
For more information please visit
Project Information
Institution:
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Specialities:
Haematology
Oncology
Other (specify below)
End date:
​
Can this be done remotely?
​
Suitability:
​
Parts of research done:
Literature review, Research proposal, Ethics approval
Positions Available:
Researchers
Statistician
Data Collector
Current Funding:
Sanofi
​
Prospective researchers receive:
​
Website
​
Project owner
Hang Quach